Q-omics provides the consensus-scored RPL21P92 profile across patient tissues and cancer cell-line models. RPL21P92 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RPL21P92 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, RPL21P92 RNA expression shows 6,241 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, THCA, and STAD as cancer lineages where RPL21P92 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL21P92 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL21P92 survival associations across molecular data types. RPL21P92 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL21P92 RNA expression–survival associations across cancer types. High RPL21P92 expression shows unfavorable associations in KIRC, SARC and CHOL, but favorable associations in COAD, PAAD and ESCA. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for RPL21P92 RNA expression.
This table summarizes RPL21P92 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL21P92. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL21P92 shows lower tumor expression in THCA and PAAD and higher tumor expression in BRCA and KIRC. The THCA box plot shows higher RPL21P92 RNA expression in normal versus tumor tissue (log2 FC = −0.049, t-test p = .006).
This table shows molecular features associated with RPL21P92 in patient tissues and cancer cell lines. In patient samples, RPL21P92 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
